- South Korea
- /
- Biotech
- /
- KOSDAQ:A196170
High Growth Tech Stocks in South Korea to Watch
Reviewed by Simply Wall St
The market in South Korea has been flat over the past week and the last 12 months, but earnings are expected to grow by 29% per annum over the next few years. In this context, identifying high-growth tech stocks with strong potential can be crucial for investors looking to capitalize on future gains.
Top 10 High Growth Tech Companies In South Korea
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Seojin SystemLtd | 33.61% | 52.05% | ★★★★★★ |
IMLtd | 21.80% | 111.43% | ★★★★★★ |
Bioneer | 23.53% | 97.58% | ★★★★★★ |
FLITTO | 32.60% | 106.82% | ★★★★★★ |
ALTEOGEN | 64.22% | 99.46% | ★★★★★★ |
NEXON Games | 29.83% | 65.02% | ★★★★★★ |
Park Systems | 23.49% | 35.59% | ★★★★★★ |
Devsisters | 25.46% | 63.02% | ★★★★★★ |
AmosenseLtd | 24.04% | 71.97% | ★★★★★★ |
UTI | 114.97% | 134.61% | ★★★★★★ |
Click here to see the full list of 49 stocks from our KRX High Growth Tech and AI Stocks screener.
Let's explore several standout options from the results in the screener.
WemadeLtd (KOSDAQ:A112040)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Wemade Co., Ltd. develops and publishes games in South Korea and internationally, with a market cap of ₩1.17 trillion.
Operations: Wemade Co., Ltd. focuses on the development and publication of video games, generating revenue primarily from game sales and related services. The company operates both domestically in South Korea and internationally.
Wemade Ltd., known for its WEMIX blockchain ecosystem, reported Q2 2024 sales of ₩332.70 billion and a net loss of ₩51.60 billion. Despite this, the company's six-month sales increased to ₩171.39 billion from last year's ₩159.28 billion, with a turnaround in net income to ₩4.11 million from a previous net loss of ₩29.08 million. The company is heavily investing in R&D, with expenses contributing significantly to their innovative WEMIX 3.0 platform aimed at enhancing dApps and GameFi solutions. The forecasted annual revenue growth rate stands at 11.1%, surpassing the KR market average of 10.8%. Earnings are expected to grow by an impressive 107.94% annually over the next three years, indicating strong future potential despite current unprofitability issues that make industry comparisons challenging for now.
- Unlock comprehensive insights into our analysis of WemadeLtd stock in this health report.
Review our historical performance report to gain insights into WemadeLtd's's past performance.
ALTEOGEN (KOSDAQ:A196170)
Simply Wall St Growth Rating: ★★★★★★
Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩17.29 billion.
Operations: The company generates revenue primarily from its biotechnology segment, amounting to ₩90.79 million. Its focus includes the development of long-acting biobetters and proprietary antibody-drug conjugates.
ALTEOGEN's recent MFDS approval for Tergase® positions it well within the high-growth tech landscape, leveraging its proprietary Hybrozyme™ Technology. The company's R&D expenditure has been substantial, with ₩64.2 billion invested in 2023 alone, contributing to a forecasted revenue growth of 64.2% per year and an expected earnings increase of 99.5% annually over the next three years. This strategic focus on innovative biologics and superior product profiles underscores its potential for significant market impact as it transitions to a commercial-stage entity.
- Navigate through the intricacies of ALTEOGEN with our comprehensive health report here.
Examine ALTEOGEN's past performance report to understand how it has performed in the past.
Lotte Energy Materials (KOSE:A020150)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Lotte Energy Materials Corporation produces and sells elecfoils in Korea and internationally, with a market cap of ₩1.91 trillion.
Operations: Lotte Energy Materials Corporation generates revenue primarily from its manufacturing sector, which accounts for ₩768.85 billion, while the service sector contributes ₩218.48 billion. The company operates in both domestic and international markets, focusing on the production and sale of elecfoils.
Lotte Energy Materials is poised for significant growth, with revenue expected to increase by 16.3% annually and earnings projected to rise by 53.7% per year, outpacing the Korean market's average of 29.2%. The company's R&D expenditure plays a crucial role in this trajectory, having invested ₩64.2 billion in the past year alone to innovate within its segments. Despite a recent one-off loss of ₩36.7 billion impacting financial results, Lotte Energy Materials' strategic focus on high-growth tech sectors ensures its potential for robust future performance.
- Click here to discover the nuances of Lotte Energy Materials with our detailed analytical health report.
Gain insights into Lotte Energy Materials' past trends and performance with our Past report.
Summing It All Up
- Unlock more gems! Our KRX High Growth Tech and AI Stocks screener has unearthed 46 more companies for you to explore.Click here to unveil our expertly curated list of 49 KRX High Growth Tech and AI Stocks.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.
Contemplating Other Strategies?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About KOSDAQ:A196170
ALTEOGEN
A bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.
Exceptional growth potential with excellent balance sheet.